second third fourth or later further line treatment option after one or more other treatment s already has have been performed used for the treatment of a patient suffering from nhl a preferred treatment cycle scheme lasts for a time period of 2 4 weeks whereby ice is preferably administered on days 1 to 3 and whereby at least one cd37 antibody preferably a2 or b2 is administered at a dose as described above either before after or simultaneously with the ice administration simultaneously hereby means on the same day s furthermore another preferred treatment cycle scheme for nhl comprises additional administration s of cd37 antibody inbetween for example once a week thus resulting in several preferably 2 to 4 most preferably 3 administrations of cd37 antibody per treatment cycle in a specific embodiment of the present invention any of the described treatment cycle schemes for ice as described in the paragraphs above is combined with the administration of an antibody targeting cd20 such as rituximab this treatment option is referred to as r ice in a preferred embodiment of the present invention any of the described treatment cycle schemes for ice cd37 mab as described in the paragraphs above is combined with the administration of an antibody targeting cd20 such as rituximab this treatment option is referred to as r ice cd37 mab in.